RestoraLAX

Quick links to important sections

RestoraLAX

Method of action: Laxative

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of RestoraLAX

Quick Facts

Property Description
Active ingredient Macrogol 3350 (Polyethylene Glycol 3350)
Form Powder for oral solution
Pharmacological class Osmotic laxative
Common use Relief of occasional constipation
Origin Synthetic (Hydrophilic Polymer)

What Type of Medicine is RestoraLAX and What is its Composition?

RestoraLAX is an Over-The-Counter (OTC) pharmaceutical product classified as an osmotic laxative, a highly clinically recognized class of agents used to relieve occasional irregularity. The medication is defined by its sole active ingredient, Macrogol 3350, which is internationally synonymous with Polyethylene Glycol 3350 (PEG 3350). This substance is a synthetic hydrophilic polymer and is supplied as a unique, tasteless, grit-free powder for oral solution that is mixed with a liquid vehicle before consumption. The medication is specifically differentiated in its market positioning for providing gentle, non-aggressive relief, avoiding the gastrointestinal urgency often associated with stimulant-based products.

How Does the Osmotic Agent Macrogol 3350 Function?

The function of the drug is based entirely on its osmotic mechanism of effect, a physical process that relies on drawing and sequestering water into the bowel lumen. Macrogol 3350 is described as a non-absorbable and biologically inert compound; it passes through the digestive tract without being absorbed into the body. This distinct mechanism ensures that the medication effectively hydrates the stool without chemically stimulating the nerve endings or muscles of the colon, providing a passive, physical means of relief that is often preferred for maintaining regularity.

What is the General Purpose of RestoraLAX?

The general purpose is to effectively restore normal bowel regularity by addressing the hardness of stool, which is a key symptom of occasional constipation. By utilizing its water-retaining mechanism to increase the water content and volume of the stool, the primary result is the softening of stool. This crucial hydration facilitates easier and more natural transit, mitigating the physical effort and discomfort that often characterize infrequent or difficult bowel movements.

Regulatory References

  1. MedlinePlus, NIH

What side effects are possible with RestoraLAX?

Possible Side Effects and Safety Information

The safety profile for Macrogol 3350 (the active ingredient in RestoraLAX) is primarily characterized by effects related to the gastrointestinal system, which align with its osmotic mechanism. Regulatory documents classify adverse reactions based on their frequency.


Frequency-Classified Adverse Reactions

Classification System-Organ Class Officially Documented Effects
Common Gastrointestinal Abdominal pain, bloating, flatulence, nausea, abdominal distension, and diarrhea (or loose stools).
Uncommon Gastrointestinal, Skin Vomiting, urgency to defecate, fecal incontinence, rash, and pruritus.
Rare Immune System Severe hypersensitivity reactions including anaphylaxis, angioedema (swelling), and dyspnoea (shortness of breath).

Safety Constraints and Considerations

The official labeling notes that gastrointestinal side effects are typically dose-dependent and usually resolve upon dose reduction or temporary cessation of treatment. The regulatory framework defines specific restrictions (contraindications) for use, including situations of known or suspected intestinal obstruction, bowel perforation, or severe inflammatory bowel diseases (such as toxic megacolon or severe ulcerative colitis).

Cautions are also noted for use in patients with an impaired gag reflex due to the oral solution format. Additionally, there is a regulatory note regarding the theoretical potential for reduced absorption of other orally administered medicines when taken simultaneously.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Macrogol 3350 (Polyethylene Glycol 3350) is officially characterized by an exaggerated osmotic effect, primarily resulting in severe or extensive diarrhea, along with symptoms such as abdominal pain, vomiting, nausea, and bloating. These manifestations of fluid loss can lead to systemic complications, including significant dehydration and critical electrolyte disturbances. In cases of massive overexposure or profound imbalance, serious outcomes documented in regulatory reports include seizures and, in rare instances, acute renal failure.

Patients considered vulnerable, such as the elderly or those with impaired hepatic or renal function, may be more susceptible to severe electrolytic disorders following an overdose.

If an overdose is suspected, immediate medical attention is required. Urgent consultation with the Poison Control helpline or emergency services must be sought if symptoms include collapse, a seizure, trouble breathing, or if the patient cannot be awakened. Furthermore, the official labeling mandates stopping use and seeking a doctor if symptoms like rectal bleeding or worsening abdominal pain or cramping occur.

Management of overdose is symptomatic and supportive, centered on the correction of fluid and electrolyte imbalances. It is officially noted that no specific antidote is known.

Therapeutic Uses of RestoraLAX

RestoraLAX: Main Uses and Benefits

RestoraLAX is an established medication used to manage occasional constipation and irregularity. Its primary function is to help relieve symptoms associated with infrequent or difficult bowel movements. The medication works by drawing water into the stool, which assists in softening it, thereby promoting increased frequency of bowel movements. This mechanism offers support for the body’s natural rhythm.

RestoraLAX is recognized as a therapeutic option for patients seeking gentle and effective relief from constipation. It is often used for short-term management of this common condition. This medication can be mixed into a variety of non-alcoholic beverages for oral intake. Polyethylene glycol 3350 is the active ingredient in this formulation, which functions as an osmotic laxative to treat occasional constipation.


Quick Facts

  • Primary Use: Provides relief from occasional constipation and irregularity.
  • Benefit: Aids in softening stool and supporting more regular bowel movements.
  • Therapeutic Domain: Used for short-term management of constipation.

Eligibility and Restrictions for Use

Who Can and Cannot Use RestoraLAX?

Eligibility to use RestoraLAX (Polyethylene Glycol 3350) is strictly defined by government regulatory agencies. The product is approved for over-the-counter (OTC) use by adults and children 17 years of age and older for the treatment of occasional constipation.

Populations That Must Not Use RestoraLAX (Contraindications)

Official labeling mandates that the medicine must not be used by individuals with certain pre-existing conditions, including a known allergy or hypersensitivity to polyethylene glycol (PEG 3350). It is also contraindicated in the presence of severe gastrointestinal issues, such as bowel obstruction, bowel perforation, ileus (paralysis of the bowel), or toxic megacolon.

Conditions Requiring Medical Consultation

Certain populations must consult a healthcare professional before use. This includes individuals who are pregnant or breastfeeding, those with kidney disease, or patients with Irritable Bowel Syndrome (IBS). Furthermore, self-treatment is not eligible if constipation persists for longer than seven days, or if symptoms like severe abdominal pain, nausea, vomiting, or rectal bleeding are present.

What should I know about interactions with other medicines?

RestoraLAX Interactions with Other Medicines and Products

Regulatory information confirms that the active ingredient in RestoraLAX, Macrogol 3350, is minimally absorbed, which limits the potential for systemic drug-drug interactions involving metabolic enzymes or transporters.

Documented Interaction Categories

Category Description of Official Caution
Physical Incompatibility Co-mixing with starch-based food thickeners is generally avoided in patients with swallowing disorders due to a documented risk of liquefaction, which increases the hazard of aspiration.
Absorption Interference The osmotic action and resulting increased speed of gastrointestinal transit may cause a transient reduction in the absorption or efficacy of co-administered orally taken medicines.
Pharmacodynamic Effects Co-administration with other laxative agents (e.g., stimulant laxatives) can lead to additive effects, increasing the risk of over-catharsis and potential adverse events.

Official Constraints and Cautions

To mitigate the potential for reduced absorption, guidance suggests avoiding the simultaneous intake of other oral medications with Macrogol 3350. Furthermore, caution is advised for patients taking Diuretics or QT-prolonging medications, as the consequences of potential fluid and electrolyte disturbances resulting from laxative overuse are heightened in these populations. The official profile does not document any systemic metabolic or transporter-based interactions.

Mechanism of Action

How RestoraLAX Works

The drug's primary action is physical and osmotic, occurring entirely within the gastrointestinal lumen and not relying on systemic absorption or specific receptor binding. Its physiological consequence results from three interconnected mechanistic steps that physically alter the colonic contents and trigger reflexive intestinal responses.

Phase 1: Osmotic Water Retention

This phase involves the drug, Polyethylene Glycol 3350, interacting with water molecules in the colon to establish a powerful osmotic gradient. By physically binding water and limiting its reabsorption, the mechanism alters the gastrointestinal water balance. This action results in an increase in the hydration and fluid content of the stool mass.

Phase 2: Volume Expansion and Physical Softening

The retention of fluid directly leads to the expansion of intraluminal stool volume and softening of the fecal consistency. This mechanistic domain ensures the colonic contents are structurally modified for subsequent transit. The resulting softer, bulkier mass creates the physical stimulus required for the next phase, which involves intrinsic intestinal reflexes.

Phase 3: Passive Colonic Motility Stimulation

The increased size of the hydrated stool distends the colonic wall, providing a mechanical signal to the intestinal muscles. This mechanism stimulates the body’s intrinsic peristalsis, promoting the transit of the now softer and more voluminous contents. The resulting physiological consequence is propulsive movement, which is triggered mechanically rather than through direct chemical stimulation of the enteric nervous system.

Dosage and Administration Information

How to Use RestoraLAX: Administration Guidelines

RestoraLAX, containing the active ingredient Macrogol 3350 (Polyethylene Glycol 3350), is administered via the oral route as a powder for solution. The usage parameters are established to ensure correct application of the osmotic agent.


Administration Parameters

Parameter Instruction
Dose 17 grams of powder
Frequency Once daily
Duration No more than 7 days for OTC use
Timing Can be taken at any time of day
Age Restriction Children 16 years of age and under: Ask a doctor

Preparation and Procedural Structure

The powder is measured to the 17 gram dose using the supplied cap or packet, then mixed into 4 to 8 ounces of any non-alcoholic liquid, such as water, juice, coffee, or tea. The powder should be fully dissolved before consumption, and the solution is not used if any clumps remain. The expected time frame for the medication to produce a bowel movement is generally within 1 to 3 days.

These instructions define the standardized, short-term usage protocol for the product, emphasizing a fixed daily dose and preparation requirements prior to oral administration.

Recent Clinical Evidence

RestoraLAX is the brand name for a laxative product containing the active ingredient polyethylene glycol 3350 (PEG 3350). PEG 3350 is classified as an osmotic laxative.


Summary of Mechanism and Action

Polyethylene glycol 3350 is a biologically inert, non-absorbable polymer. Its action in the gastrointestinal tract is primarily through osmosis. It works by binding to water molecules and retaining fluid within the stool, which helps to increase the water content and soften the stool mass. This process supports the movement of material through the colon and may lead to a more frequent and less strained bowel movement.


Clinical Trial Findings

Clinical studies, including randomized controlled trials, have examined the use of PEG 3350 for the management of occasional and chronic constipation in adults and children. Key observations from the research include:

  • Constipation Relief: Administration of PEG 3350 has been associated with an increase in the mean frequency of bowel movements per week when compared to a placebo group. In some studies, a statistically significant increase in spontaneous bowel movements (SBMs) has been noted, often within days of initiating treatment.
  • Stool Characteristics: Evidence suggests PEG 3350 may improve stool consistency and lead to a reduction in the symptoms of straining and the passage of hard or lumpy stools, based on patient self-reported data and use of the Bristol Stool Form Scale.
  • Comparative Studies: Some trials comparing PEG 3350 to other types of laxatives, such as lactulose, have found similar or favorable outcomes for PEG 3350 in terms of efficacy metrics like stool frequency and consistency. Additionally, some studies have noted that the reported incidence of certain adverse events, like abdominal pain or flatulence, may be lower with PEG 3350 than with some other laxative types.
  • Safety Profile: Across several trials, PEG 3350 was generally observed to have a low rate of treatment-emergent adverse events, with common reports including bloating and nausea. Systemic absorption of the molecule is minimal. Safety studies support its use for short-term relief of occasional constipation.

Frequently Asked Questions (FAQ)

Common questions about RestoraLAX (FAQ)


Q: Is RestoraLAX a laxative or a stool softener?

RestoraLAX is officially classified as an osmotic laxative. This means its primary action is to draw and retain water in the stool. This increase in water content helps to soften the stool mass, making it easier to pass, which aligns with the effects associated with a stool softener.


Q: How does RestoraLAX compare generally to fiber supplements?

The active ingredient in RestoraLAX, polyethylene glycol 3350, works by a specific osmotic mechanism to hydrate the stool, which differs from fiber supplements that generally add bulk. Studies have sometimes indicated that the incidence of certain gastrointestinal side effects, such as gas and bloating, may be lower compared to some bulk-forming agents.


Q: What happens if I miss a day of using RestoraLAX?

Official guidance often indicates that if a dose is missed, it should be taken when remembered, unless it is close to the next scheduled dose. In that case, the missed dose is typically skipped. It is advised to return to the regular schedule and generally not take extra medication to compensate for a missed dose.


Q: Is it okay to take RestoraLAX with vitamins or supplements?

Due to its osmotic action, RestoraLAX may increase the speed of digestive transit. This action carries a general regulatory caution that the absorption or efficacy of any co-administered oral medications (including vitamins and supplements) may be temporarily reduced. Official guidance often states that avoiding simultaneous intake of other oral products may help mitigate this potential effect.


Q: Can RestoraLAX make you feel bloated or gassy?

Yes, regulatory documents list several gastrointestinal effects as common adverse reactions. These commonly reported effects include a feeling of abdominal bloating, flatulence (gas), and nausea. These side effects are typically temporary and may be related to the drug's mechanism of action.


Q: Is abdominal cramping a common side effect of RestoraLAX?

Official safety data lists abdominal pain as a common side effect of the active ingredient. While the specific term 'cramping' may not be listed separately, it is considered one of the common gastrointestinal effects that may occur. These effects are typically mild and may be related to the drug's mechanism of action.


Q: Can RestoraLAX be used by people who are lactose intolerant?

Official product labeling for RestoraLAX powder generally indicates that the formulation is free of excipients like lactose, sugar, and salt. Due to the lack of lactose in the formulation, it is generally considered acceptable for use by individuals with lactose intolerance.


Q: Can RestoraLAX be taken with food?

The official administration instructions for the dissolved solution state that it can be taken at any time of day. This implicitly means it can be taken with or without a meal. The most important procedural requirement is that the powder must be fully dissolved in a beverage before consumption.


Q: What is the longest period of time people typically use RestoraLAX for?

For over-the-counter use, official labeling advises use for no more than seven days unless instructed by a healthcare provider. For chronic constipation, clinical studies have examined the active ingredient's safety and effectiveness over longer periods, sometimes up to six or twelve months, demonstrating sustained efficacy.


Q: Is there a taste when RestoraLAX is mixed into water or juice?

According to official product information and patient documents, the powder for oral solution is specifically described as being tasteless and unflavored. This characteristic allows it to be mixed into various common beverages without altering their taste.


Q: Does RestoraLAX interact with birth control pills?

Regulatory documents do not specifically list oral contraceptives as a documented systemic interaction. However, because the drug speeds up transit through the digestive system, a general caution exists that the absorption of any co-administered oral medicine, including birth control pills, may potentially be reduced.


Q: What are the signs that a person may be using RestoraLAX too often?

Official warnings state that signs such as severe, persistent diarrhea, increasingly loose stools, or worsening abdominal pain may be associated with the overuse or misuse of laxatives. Such effects indicate that the product may be taken in excess of the appropriate duration or dose.


Q: What should a person do if RestoraLAX does not seem to be working?

The medication is generally expected to produce a bowel movement within one to three days. Regulatory guidance indicates that if constipation persists or worsens after the expected time frame, or if a bowel movement has not occurred after seven days of use, consulting a healthcare professional is generally appropriate.


Q: What is the difference between RestoraLAX and milk of magnesia in how they work?

Both are classified as osmotic agents, working to draw water into the bowel to soften stool. RestoraLAX uses a large, inert polymer, polyethylene glycol 3350, for this effect. Milk of Magnesia uses magnesium hydroxide, a saline osmotic agent.


Q: Will RestoraLAX affect the body's natural ability to pass stool over time?

The active ingredient is non-stimulant and biologically inert, meaning it does not chemically influence the nerves or muscles of the colon. However, official warnings note that dependence can potentially occur with the overuse or prolonged misuse of any laxative, which reduces the potential for the colon to become dependent on the medication.


Q: Does RestoraLAX have any reported long-term effects?

Clinical studies on the active ingredient lasting up to 12 months generally report a low rate of adverse events, primarily those related to the digestive system. Because the drug is minimally absorbed into the body, long-term systemic effects are not typically observed, and key blood chemistry (like electrolytes) has generally remained stable in study populations.


Q: Does RestoraLAX have a high sodium content?

According to official product labeling and monographs, the powder for oral solution formulations of RestoraLAX are generally classified as sodium-free. The active ingredient is polyethylene glycol 3350, and product labeling indicates that the powder formulation typically does not include sodium-containing inactive ingredients.


Q: Is RestoraLAX safe for individuals with diabetes?

Official information indicates that the powder formulation typically contains no sugar or carbohydrates. Its minimal absorption and lack of sugar generally mean that its use does not typically require specific dose adjustments solely related to diabetes.


Q: Has RestoraLAX been studied in people with irritable bowel syndrome (IBS)?

Yes, clinical trials have been conducted to assess the effects of the active ingredient in individuals diagnosed with Irritable Bowel Syndrome with Constipation (IBS-C). However, the official guidance for the product advises that individuals with IBS should consult a healthcare professional before beginning use.


Q: What are the ingredients in RestoraLAX other than the active one?

The common powder for solution formulations of RestoraLAX are unique in that they typically contain only one ingredient: the active ingredient, polyethylene glycol 3350 (PEG 3350). No inactive ingredients, flavorings, or excipients are usually listed.


Q: Does RestoraLAX cause electrolyte imbalances?

The official safety profile advises caution regarding the theoretical potential for fluid and electrolyte disturbances if the product is overused or misused. However, when taken at the recommended dose, studies over extended periods (up to 12 months) have generally shown no clinically significant changes in electrolyte levels.


Q: Will stopping RestoraLAX suddenly cause rebound constipation?

The drug's non-stimulant mechanism of action suggests a low risk of rebound constipation, which is often associated with stimulant laxatives. However, studies have noted that patients may experience a recurrence of their original constipation symptoms shortly after stopping treatment.


Q: Is RestoraLAX available in different forms, such as capsules or liquid?

The common RestoraLAX brand product available over-the-counter is officially described as a powder for oral solution. While the active ingredient itself may appear in different forms under other brand names or as prescription items, the standard OTC product is the powder.

How should RestoraLAX be stored and disposed of?

How to Store and Dispose of RestoraLAX?

The storage of RestoraLAX (polyethylene glycol 3350) must adhere to conditions mandated by regulatory labeling to maintain product quality.

Storage Requirements

  • Temperature: Store the powder at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). Storage excursions up to 30°C (86°F) are acceptable.
  • Protection: The container must be kept tightly closed and stored away from excess heat, moisture, and direct light; the product must not be frozen.
  • Child Safety: Keep all containers out of the sight and reach of children.
  • Reconstituted Solution: If the product is prepared as a solution (for certain high-dose formulations), it must be discarded after 48 hours, even if refrigerated.

Disposal Instructions

Expired or unused RestoraLAX should not be flushed down the toilet or poured down the sink. The preferred method for disposal is through an official drug take-back program. If one is unavailable, the powder can be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of RestoraLAX found in:

A-Z Index: